Exactly how closely NF1 mutations predict protein loss has not been thoroughly studied using clinically relevant samples, and currently there are no protein-based NF1 diagnostics used to guide the endocrine treatment in ER+ breast cancer. The gene discussed is NF1; the disease is breast carcinoma.